EMA Authorised: Polivy (polatuzumab vedotin) — Roche Registration GmbH

View source ↗

Summary

The European Medicines Agency authorised Polivy (polatuzumab vedotin) from Roche Registration GmbH for a B-cell lymphoma indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Polivy (polatuzumab vedotin)

Snippet

Status: Authorised. Therapeutic area: Lymphoma, B-Cell. MAH: Roche Registration GmbH. Decision date: 16/10/2025. Orphan medicine